- Home
- GRND vs BEAM Comparison
GRND vs BEAM Comparison
Compare GRND & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- BEAM
- Stock Information
- Founded
- GRND 2009
- BEAM 2017
- Country
- GRND United States
- BEAM United States
- Employees
- GRND N/A
- BEAM N/A
- Industry
- GRND Computer Software: Prepackaged Software
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRND Technology
- BEAM Health Care
- Exchange
- GRND Nasdaq
- BEAM Nasdaq
- Market Cap
- GRND 2.5B
- BEAM 2.3B
- IPO Year
- GRND N/A
- BEAM 2020
- Fundamental
- Price
- GRND $12.95
- BEAM $25.14
- Analyst Decision
- GRND Strong Buy
- BEAM Strong Buy
- Analyst Count
- GRND 5
- BEAM 12
- Target Price
- GRND $22.40
- BEAM $48.09
- AVG Volume (30 Days)
- GRND 2.0M
- BEAM 2.3M
- Earning Date
- GRND 11-06-2025
- BEAM 11-04-2025
- Dividend Yield
- GRND N/A
- BEAM N/A
- EPS Growth
- GRND N/A
- BEAM N/A
- EPS
- GRND N/A
- BEAM N/A
- Revenue
- GRND $411,545,000.00
- BEAM $55,701,000.00
- Revenue This Year
- GRND $28.55
- BEAM N/A
- Revenue Next Year
- GRND $22.20
- BEAM $19.01
- P/E Ratio
- GRND N/A
- BEAM N/A
- Revenue Growth
- GRND 28.97
- BEAM N/A
- 52 Week Low
- GRND $11.73
- BEAM $13.53
- 52 Week High
- GRND $25.13
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- GRND 41.76
- BEAM 58.18
- Support Level
- GRND $11.81
- BEAM $20.23
- Resistance Level
- GRND $14.13
- BEAM $22.72
- Average True Range (ATR)
- GRND 0.58
- BEAM 1.68
- MACD
- GRND -0.16
- BEAM 0.36
- Stochastic Oscillator
- GRND 30.16
- BEAM 97.41
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.